Kidney transplantation in highly sensitized patients

British Medical Bulletin

Volumn 114, Issue 1, 2015, Pages 113-125

  Jordan, Stanley C ^a   Choi, Jua ^a   Vo, Ashley ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibody mediated rejection; C1 inhibitor; Complement; Desensitization; Eculizumab; IL 6; Immunotherapy; IVIG; Kidney transplant; Rituximab

Indexed keywords

B LYMPHOCYTE ANTIBODY; BELIMUMAB; BORTEZOMIB; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 6; PROTEINASE INHIBITOR; RITUXIMAB; TOCILIZUMAB; COMPLEMENT; ECULIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP TYPING; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH CARE SYSTEM; HLA SYSTEM; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOMODULATION; IMMUNOPATHOLOGY; KIDNEY ALLOGRAFT; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; SYSTEMATIC DESENSITIZATION; DESENSITIZATION; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; BORTEZOMIB; COMPLEMENT SYSTEM PROTEINS; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; RITUXIMAB;

EID: 84942012627     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv013     Document Type: Article

References (62)

1. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9.
2. Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol 2011;6:1774-80.
3. Loupy A, Hill GS, Jordan SC. The impact of donorspecific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012;8:348-57.
4. Organ Procurement and Transplantation Network (OPTN). Scientific Registry of Transplant Recipients. 2012 Annual Data Report, 2012.
5. Vo AA, Choi J, Cisneros K, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359: 242-51.
6. Scientific Registry of Transplant Recipients. http://srtr. transplant.hrsa.gov/Resources.aspx (9 January 2014, date last accessed).
7. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;76:631-6.
8. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011;365:318-26.
9. Kahwaji J, Najjar R, Kancherla D, et al. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant 2014;28:546-53.
10. Lefaucheur C, Loupy A, Vernerey D, et al. Antibodymediated vascular rejection of kidney allografts: a population-based study. Lancet 2013;381:313-9.
11. Jordan SC, Vo AA. Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am J Kidney Dis 2012; 59:758-60.
12. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011;11:896-906.
13. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010;24(Suppl. 1):S7-27.
14. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-62.
15. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010;89:1095-102.
16. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013;95:852-8.
17. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012;94:345-51.
18. Pondrom S. The IVIg dilemma. Am J Transplant 2014; 14:2195-6.
19. Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014;14:1573-80.
20. Vo AA, Sinha A, Haas M, et al. Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 2015. [Epub ahead of print].
21. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 2014;98:312-9.
22. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009;88:1-6.
23. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982;306:1254-8.
24. Tjon AS, Tha-In T, Metselaar HJ, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 2013;173:259-67.
25. Matta BM, Lott JM, Mathews LR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol 2014;193:4010-20.
26. Paquin Proulx D, Aubin E, Lemieux R, et al. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol 2010;135: 422-9.
27. Abu Jawdeh BG, Cuffy MC, Alloway RR, et al. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant 2014;28:494-507.
28. Jordan SC, Kahwaji J, Toyoda M, et al. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011;16:416-24.
29. Rothstein TL. Grand challenges in B cell biology. Front Immunol 2011;2:2.
30. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264-83.
31. Hobeika E, Nielsen PJ, Medgyesi D. Signaling mechanisms regulating B-lymphocyte activation and tolerance. J Mol Med (Berl) 2015;93:143-58.
32. Hilgenberg E, Shen P, Dang VD, et al. Interleukin-10-producing B cells and the regulation of immunity. Curr Top Microbiol Immunol 2014;380:69-92.
33. Fillatreau S. Pathogenic functions of B cells in autoimmune diseases: IFN-? production joins the criminal gang. Eur J Immunol 2015;45:966-70.
34. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209:1001-10.
35. Morsy DE, Sanyal R, Zaiss AK, et al. Reduced T-dependent humoral immunity in CD20-deficient mice. J Immunol 2013;191:3112-8.
36. Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010;120:214-22.
37. Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease. Lancet 2014. [Epub ahead of print].
38. Zachary AA, Eng HS. Desensitization: achieving immune detente. Tissue Antigens 2011;77:3-8.
39. Jackson AM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 2015;87:409-16.
40. Kohei N, Hirai T, Omoto K, et al. Chronic antibodymediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012;12:469-76.
41. Lynch RJ, Silva IA, Chen BJ, et al. Cryptic B cell response to renal transplantation. Am J Transplant 2013;13: 1713-23.
42. van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 2015;15:407-16.
43. Böhmig GA,Wahrmann M, Bartel G. Transplantation of the broadly sensitized patient: what are the options? Curr Opin Organ Transplant 2011;16:588-93.
44. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donorspecific antibodies: a pilot study. Transplantation 2010; 89:1403-10.
45. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011;92:48-53.
46. McLaughlin M, Östör's A. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Expert Opin Drug Saf 2015;14:429-37.
47. Kim I, Wu G, Chai NN, et al. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation 2014. [Epub ahead of print].
48. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:a016295.
49. Leone A, Sciascia S, Kamal A, et al. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 2015;11:109-16.
50. Johansson BP, Shannon O, Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS ONE 2008;3:e1692.
51. Loupy A, Lefaucheur C, Vernerev D, et al. Complementbinding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369:1215-26.
52. Sarma JV, Ward PA. The complement system. Cell Tissue Res 2011;343:227-35.
53. Sahu A, Morikis D, Lambris J. Complement inhibitor targeting C3,C4, and C5. In: Lambris J (ed). Therapeutic Interventions in the Complement System, vol. 4 Totowa, NJ: Humana Press Inc., 2000,75-112.
54. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008;632:273-92. 2008, Springer Science.
55. Cravedi P, Heeger PS. Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest 2014;124:2348-54.
56. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-13.
57. Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients Posted, 2015. http://news.alexionpharma.com/press-release/companynews/alexion-provides-update-phase-2-clinical-trialeculizumab-antibody-mediat.
58. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013;13:2179-85.
59. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8: 643-57.
60. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012;12:431-42.
61. Vo AA, Zeevi A, Choi J, et al. A phase I/II placebo-controlled trial of c1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 2015;99:299-308.
62. Damman J, Bloks VW, Daha MR, et al. Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. Transplantation 2014. [Epub ahead of print].